EOM Pharmaceutical Holdings Inc. (IMUC)

[maverick_1]

Today's VERY Subpar data not a surprise and Increase in Authorized is a prelude to future capital raise or Reverse Split.

Watch out if these two 13D filers as reported in recent Proxy start UNloading:


Name and Address of Beneficial Owner (1)

Shares
Beneficially
Owned (2) Percent of
Total
Sabby Healthcare Master Fund, Ltd. and an affiliated entity (3)
c/o Ogier Fiduciary Services (Cayman) Limited
89 Nexus Way
Camana Bay, Grand Cayman KY1-9007
Cayman Islands
8,325,000 9.22 %
Capital Ventures International (4)
The Harbour Trust Co. Ltd.
Windward 1, Regatta Office Park
West Bay Road
P.O. Box 897
Grand Cayman KY1-1103
Cayman Islands.
5,000,000 5.54 %



Here's the top holders re nasdaq.com site:
Owner Name Date Shared Held Change (Shares) Change (%) Value (in 1,000s)
SABBY MANAGEMENT, LLC 09/30/2015 4,169,243 (1,702,573) (29) 2,164
VANGUARD GROUP INC 09/30/2015 2,561,674 27,454 1.08 1,330
BAILARD, INC. 09/30/2015 2,250,000 956,828 73.99 1,168
RENAISSANCE TECHNOLOGIES LLC 09/30/2015 1,181,400 (521,292) (30.62) 613
GEODE CAPITAL MANAGEMENT, LLC 09/30/2015 439,847 0 0.00 228


Read more: http://www.nasdaq.com/symbol/imuc/institutional-holdings#ixzz3s3QbMc00

AND

MORE LIKELY than not for subpar data today as I pointed out which some can't wrap around the vacuum up there:

maverick_1 Saturday, 08/22/15 07:36:30 PM
Re: maverick_1 post# 3365
Post #
3367
of 3430 Go
Another Confirmatory: ICT107 only 6 Antigen:

From IMUC website: (can't copy and paste, so see for yourself)
http://www.imuc.com/pipeline

but here copy and pasted from Mar 2015 IMUC 10K:
Quote:
Item 1.
Business.
ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of cancers. Immunotherapy is an emerging approach to treating cancer in which a patient’s own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies. While some other cancer immunotherapies only target a single cancer antigen, our technology can elicit an immune response against several antigens. Our cancer immunotherapies are also distinguished by the fact that they target cancer stem cells (CSCs), which are the primary drivers of tumor growth and disease recurrence. Our most advanced product candidate, ICT-107, completed phase II testing in December 2013, and we have received feedback from both the U.S. and European Union (EU) regulatory agencies that supports our plans for moving forward into phase III testing. In addition, we have a portfolio of other potential therapeutic immunotherapies using our proprietary approach to treating cancer.
ICT-107, our lead product candidate, is a dendritic cell (DC) vaccine for the treatment of newly diagnosed glioblastoma multiforme (GBM), the most common and lethal type of brain cancer. ICT-107 is designed to activate a patient’s immune system to target six different tumor-associated antigens. The recently completed phase II testing of ICT-107 involved a clinical trial designed as a double-blind, placebo-controlled (2:1 randomized), multicenter evaluation of the safety and efficacy of ICT-107 in patients with newly diagnosed GBM. From January 2011 until September 2012, the trial enrolled 278 patients at 25 centers throughout the U.S. and 124 patients were randomized to ICT-107 or placebo. In December 2013, we reported that ICT-107 treated patients had a numerical advantage in overall survival (OS) of two months more than placebo patients in the intent-to-treat (ITT) population but that the difference in survival between ICT-107 and placebo treated patients (the primary efficacy endpoint of the trial), did not reach statistical significance (p-value = 0.58; Hazard Ratio = 0.87). For Progression-Free Survival (PFS), an important secondary efficacy endpoint, we reported ICT-107 treated patients had a two-month advantage in median PFS compared with placebo patients in the ITT population. This difference in PFS between ICT-107 and placebo treated patients reached statistical significance (p-value = 0.014; Hazard Ratio = 0.56). ICT-107 was generally well tolerated, with no imbalance in adverse events between the treated and placebo groups.


Investing your hard earned $'s in high risk biotec's is never easy.

Much WORST if proper due diligence is NOT performed which I have performed for YOU! There are also many other innumerable factors to cite.

And iHub's member meter for # of followers and # of posts mean little IMHO after perusing thru hundreds of iHub posters since joining.

GLTA